# Etoposide

## Fytosid inj 100mg/5mL

##### 臨採

| TAH Drug Code      | [**IFYT**](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=IFYT)                                                                                                                                                                                                                                                                                                              |
|:-------------------|:--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Small cell carcinoma of lung, In combination with other approved chemotherapeutic agents as first line, Testicular cancer, In combination with other approved chemotherapeutic agents in patients with refractory testicular tumors who have already received appropriate surgical, chemotherapeutic, and radiotherapeutic therapy                                                    |
| Dosing             | [Testicular cancer (combination chemotherapy)] Usual dose ranges from 50-100 mg/m2/day on days 1 through 5 to 100 mg/m2/day on days 1, 3 and 5. [Small cell lung cancer (combination chemotherapy)] Usual dose ranges from 35 mg/m2/day for 4 days to 50 mg/m2/day for 5 days. Chemotherapy courses are repeated at 3- to 4-week intervals after adequate recovery from any toxicity. |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                         |
| Renal Impairment   | Dose adjustment required                                                                                                                                                                                                                                                                                                                                                              |
| Contraindications  | Hypersensitivity to etoposide or any component of the formulation. Severe leukopenia or thrombocytopenia; severe hepatic impairment; severe renal impairment                                                                                                                                                                                                                          |
| Adverse Effects    | Alopecia, Shivering, Diarrhea, Inflammatory disease of mucous membrane, Loss of appetite, Nausea, Vomiting, Asthenia, Fever, Malaise                                                                                                                                                                                                                                                  |
| Pregnancy          | Human (and Animal) Data Suggest Risk                                                                                                                                                                                                                                                                                                                                                  |
| Lactation          | Contraindicated                                                                                                                                                                                                                                                                                                                                                                       |

## Vepesid 50mg (專案進口)

##### 臨採

| TAH Drug Code      | [**OVEP5**](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=OVEP5)                                                                                                                                                                                                                                                                                                                                |
|:-------------------|:----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Small cell carcinoma of lung, In combination with other approved chemotherapeutic agents as first line, Testicular cancer, In combination with other approved chemotherapeutic agents in patients with refractory testicular tumors who have already received appropriate surgical, chemotherapeutic, and radiotherapeutic therapy                                                                        |
| Dosing             | (無TFDA仿單) (US FDA仿單) [Testicular cancer] dose ranges from 50-100 mg/m2/day on days 1 through 5 to 100 mg/m2/day on days 1, 3, and 5 in combination with other approved chemotherapeutic agents. [Small cell lung cancer] dose ranges from 35 mg/m2/day for 4 days to 50 mg/m2/day for 5 days. Chemotherapy courses are repeated at 3- to 4-week intervals after adequate recovery from any toxicity. |
| Hepatic Impairment | Dose adjustment required                                                                                                                                                                                                                                                                                                                                                                                  |
| Renal Impairment   | Dose adjustment required                                                                                                                                                                                                                                                                                                                                                                                  |
| Contraindications  | Hypersensitivity to etoposide or any component of the formulation. Severe leukopenia or thrombocytopenia; severe hepatic impairment; severe renal impairment                                                                                                                                                                                                                                              |
| Adverse Effects    | Alopecia, Shivering, Diarrhea, Inflammatory disease of mucous membrane, Loss of appetite, Nausea, Vomiting, Asthenia, Fever, Malaise                                                                                                                                                                                                                                                                      |
| Pregnancy          | Human (and Animal) Data Suggest Risk                                                                                                                                                                                                                                                                                                                                                                      |
| Lactation          | Contraindicated                                                                                                                                                                                                                                                                                                                                                                                           |

